Bright Minds Biosciences said the FDA placed its experimental seizure drug BMB-101 on a partial clinical hold. The company tied the hold to toxicity issues identified in preclinical mouse models. A partial hold typically restricts certain trial activities while regulators review specific safety questions. Bright Minds indicated the action followed regulator findings on nonclinical tolerability, shifting attention to how the sponsor will address the underlying toxicology concerns. The announcement is another signal of how tightly FDA will scrutinize preclinical safety packages for early-stage neuroscience assets before broader patient enrollment or continuation.